You are here

SARC028

Active
A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas
Type of Sarcoma: 
Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma
Drug: 
Pembrolizumab
Accrual Status: 
Recruiting
Overall Study Principal Investigator: 
Hussein Tawbi, MD
Associate Professor of Medicine
MD Anderson Cancer Center

For more information about this trial and open sites: